Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 3/20 | 0.48 |
| ▸ | CCNK | O75909 | 2/20 | 0.47 |
| ▸ | CDK12 | Q9NYV4 | 2/20 | 0.47 |
| ▸ | HTR2C | P28335 | 7/20 | 0.43 |
| ▸ | HTR2B | P41595 | 4/20 | 0.43 |
| ▸ | TERT | O14746 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8057395 | 1.00 | PRCP (0.48) | PRCPCCNKCDK12HTR2CHTR2B | |
| SCHEMBL19051493 | 0.96 | PRCP (0.44) | PRCPCCNKCDK12HTR2CHTR2B | |
| SCHEMBL2822143 | 0.80 | ALDH1A1 (0.50) | KDM4E | |
| SCHEMBL3207976 | 0.79 | GNAI3 (0.45) | KDM4E | |
| SCHEMBL8066737 | 0.79 | CTSC (0.34) | — | |
| SCHEMBL18381195 | 0.79 | SMN1; SMN2 (0.41) | KDM4EHTR2A | |
| SCHEMBL18048893 | 0.76 | CTSC (0.45) | HTR2CHTR2BTERT | |
| SCHEMBL18048894 | 0.76 | CTSC (0.45) | HTR2CHTR2BTERT | |
| SCHEMBL3333627 | 0.75 | CCNK (0.50) | PRCPCCNKCDK12HTR2CHTR2B | |
| SCHEMBL18154904 | 0.75 | PRCP (0.49) | PRCPCCNKCDK12HTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7683097-B2 | Topoisomerase inhibitors | Propharmacon Inc. (US) | 2010-03-23 | — | — | US | claimed |
| US-7683097-B2 | Topoisomerase inhibitors | Propharmacon Inc. (US) | 2010-03-23 | — | — | US | disclosed |
| US-20070004701-A1 | Topoisomerase inhibitors | PROPHARMACON, INC. (US) | 2007-01-04 | — | — | US | disclosed |
| WO-2006022955-A2 | TOPOISOMERASE INHIBITORS | PROPHARMACON, INC. (US) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004701-A1 | Topoisomerase inhibitors | TOP1, TOP2A, TOP2B | PRCP 1808/4885CCNK 138/4885CDK12 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.